# Metroplex Clinical Research Center

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/metroplex-clinical-research-center/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 87 |
| Citations | 43,298 |
| City | Dallas |
| Country | US |
| Description | Metroplex Clinical Research Center is a research organisation in Dallas, US. OpenAlex records 531 works and 43,298 citations for it. 42 researchers list it as their most recent affiliation. |
| Homepage | http://www.mcrcdallas.com/ |
| OpenAlex ID | https://openalex.org/I4210096290 |
| Region | Texas |
| Researchers | 42 |
| ROR ID | https://ror.org/00y21a678 |
| Type | facility |
| Works | 531 |

## University papers

- [Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis](https://scholariq.org/papers/placebo-controlled-trial-of-tofacitinib-monotherapy-in-rheumatoid-arthritis/)
- [Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis](https://scholariq.org/papers/tofacitinib-or-adalimumab-versus-placebo-in-rheumatoid-arthritis/)
- [Tofacitinib versus Methotrexate in Rheumatoid Arthritis](https://scholariq.org/papers/tofacitinib-versus-methotrexate-in-rheumatoid-arthritis/)
- [Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study](https://scholariq.org/papers/tofacitinib-cp-690-550-in-patients-with-rheumatoid-arthritis-receiving/)
- [Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis](https://scholariq.org/papers/tofacitinib-in-combination-with-nonbiologic-disease-modifying-antirheumatic/)
- [Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu](https://scholariq.org/papers/tocilizumab-inhibits-structural-joint-damage-in-rheumatoid-arthritis-patients/)
- [Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs](https://scholariq.org/papers/phase-iib-dose-ranging-study-of-the-oral-jak-inhibitor-tofacitinib-cp-690-550-or/)

## University top topics

Showing 8 of 25.

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Autoimmune and Inflammatory Disorders Research](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders-research/)
- [Biosimilars and Bioanalytical Methods](https://scholariq.org/topics/biosimilars-and-bioanalytical-methods/)
- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.